309 related articles for article (PubMed ID: 31982490)
1. Role of heterogeneous regulatory T cells in the tumor microenvironment.
Wei T; Zhong W; Li Q
Pharmacol Res; 2020 Mar; 153():104659. PubMed ID: 31982490
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
3. Induced regulatory T cells in inhibitory microenvironments created by cancer.
Whiteside TL
Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
[TBL] [Abstract][Full Text] [Related]
4. The function and potential drug targets of tumour-associated Tregs for cancer immunotherapy.
Yan S; Zhang Y; Sun B
Sci China Life Sci; 2019 Feb; 62(2):179-186. PubMed ID: 30610537
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
6. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cell: a protection for tumour cells.
Wang Y; Ma Y; Fang Y; Wu S; Liu L; Fu D; Shen X
J Cell Mol Med; 2012 Mar; 16(3):425-36. PubMed ID: 21895966
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV.
Pakravan N; Hassan ZM
Immunotherapy; 2018 Mar; 10(3):213-219. PubMed ID: 29370722
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
10. The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment.
Hu C; Jiang X
Biomed Pharmacother; 2017 Apr; 88():134-137. PubMed ID: 28103506
[TBL] [Abstract][Full Text] [Related]
11. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
[TBL] [Abstract][Full Text] [Related]
12. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.
Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A
Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474
[TBL] [Abstract][Full Text] [Related]
14. The Dual Role of Treg in Cancer.
Frydrychowicz M; Boruczkowski M; Kolecka-Bednarczyk A; Dworacki G
Scand J Immunol; 2017 Dec; 86(6):436-443. PubMed ID: 28941312
[TBL] [Abstract][Full Text] [Related]
15. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
16. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
19. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
20. Inflammation in the Tumor Microenvironment.
Lin Q; Jin S; Han M; Zheng W; Liu J; Wei X
J Immunol Res; 2018; 2018():1965847. PubMed ID: 30035130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
